A Phase I Multiple Ascending Dose Study of MK-3508 in Healthy Participants for the Treatment of Respiratory Syncytial Virus Infection

The primary objective of the study titled "MK-3508 Multiple Ascending Dose Study in Healthy Participants" is to evaluate the safety and tolerability of the investigational product in the context of **respiratory syncytial virus infection**. This is clinically relevant as it aims to assess the potential of the investigational product to be used in the prevention or treatment of this common and potentially severe viral infection. The study does not list any secondary objectives.

The clinical trial involves participants diagnosed with **respiratory syncytial virus infection**. The study population includes both male and female subjects, with an age range categorized under code "3", which typically represents a specific age group, though the exact range is not specified. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria, including lifestyle considerations such as diet, physical activity, or habits, are not detailed in the available data. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the safety and efficacy of a new investigational product in the treatment of **respiratory syncytial virus infection**. This study is a Phase 3, randomized, double-blind, controlled trial. The trial is expected to commence recruitment on October 4, 2023, and is estimated to conclude by December 29, 2023. Participants will be randomly assigned to receive either the investigational product or a placebo, ensuring that neither the participants nor the investigators are aware of the group assignments, thus maintaining the double-blind nature of the study.

The trial will include several key study visits. Initially, a screening visit will be conducted to assess the eligibility of potential participants based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled in the study and will undergo a series of follow-up visits at specified intervals to monitor their health status and response to the treatment. These visits will include assessments such as physical examinations, laboratory tests, and questionnaires to gather data on the primary and secondary endpoints of the study. The end-of-study visit will mark the completion of the participant's involvement, during which final evaluations will be conducted to ensure participant safety and to collect comprehensive data for analysis.

The expected duration of participant involvement in the trial will vary depending on the individual response to treatment and adherence to the study protocol. Participants may be withdrawn from the study early if they experience adverse events that compromise their safety, if they fail to comply with the study requirements, or if they choose to withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants throughout the study duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is in Phase 3, with an estimated recruitment start date of October 4, 2023, and an estimated end date of December 29, 2023. Efficacy will be assessed through a structured evaluation process, although specific parameters or endpoints for efficacy assessment are not detailed in the available data. The trial will follow a systematic approach to measure, collect, and analyze efficacy data, adhering to the standards expected in Phase 3 trials. The trial's design will likely involve the use of validated scales, laboratory tests, or patient-reported outcomes to ensure the reliability and validity of the efficacy assessments. The schedule for these assessments will be aligned with the trial's timeline, ensuring that data collection is consistent and comprehensive throughout the study period. The trial will employ rigorous methods to analyze the collected data, ensuring that the efficacy outcomes are accurately determined and reported.